Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Mesa Verde Venture Partners

Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Read the press release here: https://loom.ly/1Pu09G0

#cancertreatment #biopharma #sciencenews

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Read the press release here: https://loom.ly/4PQGN9c

#science #biopharma #cancertreatment #multiplemyeloma #car-t

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Read the press release here: https://loom.ly/HCKoAzU

#cancertreatment #science #biopharma

Immix Biopharma is pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ 

Read more here: https://lnkd.in/emdDgvbQ

#science #cancertreatment #technology

Immix Biopharma's subsidiary Nexcella, Inc. 

Learn more about Nexcella, Inc.: https://nexcella.com/  

#biopharma #cancertreatment #science

Who founded Immix Biopharma?

Read more here: https://lnkd.in/enZ6FH3s 

#science #cancer #biopharma

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

#healthcare #science #biopharma

Dr. Suzanne Lentzsch Joins Immix Biopharma Scientific Advisory Board

Read the press release here: https://loom.ly/spWfYjU

#sciencenews #biopharma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for the following: 

Read the press release here: https://loom.ly/fwrLYNQ

#fda #science #cancer

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Read the press release here: https://loom.ly/fwrLYNQ 

#science #biopharma #sciencenews

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	247.54K -	252.34K 1.94%	142.94K 43.36%	1.27M 790.79%	1.43M 12.54%
accumulated other comprehensive income loss	68.22K -	131.86K 93.28%	125.41K 4.89%	87.02K 30.61%	134.67K 54.75%
cash and cash equivalents	734.01K -	391.09K 46.72%	17.64M 4,411.66%	13.44M 23.85%	17.51M 30.31%
cash and short term investments	734.01K -	391.09K 46.72%	17.64M 4,411.66%	13.44M 23.85%	17.51M 30.31%
common stock	338 -	338 0%	1.32K 291.42%	1.40K 5.59%	2K 43.16%
deferred revenue		342.84K -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt
long term investments
net debt	3.37M -	3.71M 10.19%	-17.59M 574.38%	-13.44M 23.63%	-17.51M 30.31%
net receivables	175.75K -	127.44K 27.49%	25.72K 79.82%	255.71K 894.11%	1.17M 358.41%
other assets
other current assets	23.50K -	13.71K 41.64%	516.19K 3,663.99%	1.21M 133.52%	1.11M 8.26%
other current liabilities	241.76K -	575K 137.84%	9.10K 98.42%		2.29M -
other liabilities
other non current assets				6.72K -	87.23K 1,197.28%
other non current liabilities				475K -
othertotal stockholders equity	508.87K -	508.87K 0%	47.62M 9,257.73%	51.06M 7.22%	69.68M 36.48%
preferred stock
property plant equipment net	9.68K -	7.36K 23.97%	5.70K 22.63%	3.56K 37.49%	50.18K 1,309.58%
retained earnings	-4.22M -	-5.37M 27.18%	-29.76M 453.94%	-37.99M 27.66%	-53.41M 40.61%
short term debt	4.10M -	4.10M 0%	50K 98.78%
short term investments
tax assets
tax payables
total assets	942.94K -	539.60K 42.78%	18.19M 3,271.42%	14.91M 18.05%	19.93M 33.65%
total current assets	933.26K -	532.24K 42.97%	18.19M 3,316.98%	14.90M 18.08%	19.79M 32.82%
total current liabilities	4.59M -	5.27M 14.84%	202.04K 96.17%	1.27M 530.22%	3.72M 192.30%
total debt	4.10M -	4.10M 0%	50K 98.78%
total investments
total liabilities	4.59M -	5.27M 14.84%	202.04K 96.17%	1.75M 765.33%	3.72M 112.88%
total liabilities and stockholders equity	942.94K -	539.60K 42.78%	18.19M 3,271.42%	14.91M 18.05%	19.93M 33.65%
total non current assets	9.68K -	7.36K 23.97%	5.70K 22.63%	10.28K 80.58%	137.41K 1,236.15%
total non current liabilities				475K -
total stockholders equity	-3.65M -	-4.73M 29.73%	17.99M 480.29%	13.16M 26.85%	16.41M 24.66%

NASDAQ:IMMX

Immix Biopharma, Inc.

Last Close

2.15

26/07 20:00

Market Cap

53.89M

Beta: -

Volume Today

125.04K

Avg: 208.58K

PE Ratio

−4.23

PFCF: −5.01

Preview